NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and......
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second qu......
My ENet App consolidates all subscriber services, eSIM provisioning and payments into one platform, with a built-in digital wallet unlocking new revenue streams for ENet
Ant Group's 2025 Sustainability Report disclosed a record R&D investment of USD 5.17 billion (RMB 35.03 billion) in 2025—the fifth straight year of growth—alongside AI-powered green computing breakt......
